In last trading session, Viking Therapeutics Inc (NASDAQ:VKTX) saw 3.52 million shares changing hands with its beta currently measuring 0.75. Company’s recent per share price level of $25.66 trading at -$0.13 or -0.50% at ring of the bell on the day assigns it a market valuation of $2.88B. That closing price of VKTX’s stock is at a discount of -219.02% from its 52-week high price of $81.86 and is indicating a premium of 26.27% from its 52-week low price of $18.92. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 4.3 million shares which gives us an average trading volume of 4.62 million if we extend that period to 3-months.
For Viking Therapeutics Inc (VKTX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.22. Splitting up the data highlights that, out of 7 analysts covering the stock, 0 rated the stock as a Sell while 1 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.43 in the current quarter.
Viking Therapeutics Inc (NASDAQ:VKTX) trade information
Upright in the red during last session for losing -0.50%, in the last five days VKTX remained trading in the green while hitting it’s week-highest on Wednesday, 04/23/25 when the stock touched $25.66 price level, adding 4.79% to its value on the day. Viking Therapeutics Inc’s shares saw a change of -36.23% in year-to-date performance and have moved 8.73% in past 5-day. Viking Therapeutics Inc (NASDAQ:VKTX) showed a performance of -8.29% in past 30-days. Number of shares sold short was 25.62 million shares which calculate 6.42 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 110 to the stock, which implies a rise of 76.67% to its current value. Analysts have been projecting 74 as a low price target for the stock while placing it at a high target of 110. It follows that stock’s current price would drop -188.39% in reaching the projected high whereas dropping to the targeted low would mean a loss of -188.39% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -23.00% during past 5 years.
Viking Therapeutics Inc (NASDAQ:VKTX)’s Major holders
Insiders are in possession of 2.12% of company’s total shares while institution are holding 74.39 percent of that, with stock having share float percentage of 76.00%. Investors also watch the number of corporate investors in a company very closely, which is 74.39% institutions for Viking Therapeutics Inc that are currently holding shares of the company. FMR LLC is the top institutional holder at VKTX for having 16.54 million shares of worth $876.8 million. And as of 2024-06-30, it was holding 14.9835 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 10.1 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.147 of outstanding shares, having a total worth of $535.26 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and SPDR SERIES TRUST-SPDR(R) S&P(R) Biotech ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 3.3 shares of worth $84.75 million or 2.94% of the total outstanding shares. The later fund manager was in possession of 2.89 shares on Feb 28, 2025 , making its stake of worth around $74.1 million in the company or a holder of 2.57% of company’s stock.
